2025-12-22 - Analysis Report
Okay, here is a comprehensive analysis of Eli Lilly and Co (LLY) based on the provided data.

**0. Overview**

This report provides an analysis of Eli Lilly and Co. (LLY) stock, comparing its performance against the S&P 500 (VOO), examining recent indicators, news, analyst opinions, earnings, and financial data.  It aims to provide a concise overview for potential investment decisions.

**1. Return Rate Analysis**

*   **Company Overview:** Eli Lilly and Co is a global pharmaceutical company focused on discovering, developing, manufacturing, and marketing pharmaceutical products.
*   **LLY Cumulative Return:** 305.60%
*   **VOO Cumulative Return:** 100.88%
*   **Divergence:** 204.7 (Relative Divergence: 84.5)

**Analysis:**

LLY has significantly outperformed the S&P 500. The divergence of 204.7 indicates a substantial performance gap.  The relative divergence of 84.5 suggests that the current performance gap is in the upper quartile of historical divergence between the two. This highlights the strength of LLY's recent performance relative to the broader market.

**Alpha, Beta, CAGR, MDD Analysis:**

| Year       | CAGR   | MDD    | Alpha   | Beta   | Cap(B) |
|------------|--------|--------|---------|--------|--------|
| 2015-2017  | 11.0%  | 76.1%  | -17.0%  | -0.0   | 75.7   |
| 2016-2018  | 39.0%  | 68.9%  | 24.0%   | -0.0   | 103.7  |
| 2017-2019  | 41.0%  | 68.9%  | 19.0%   | 0.4    | 117.8  |
| 2018-2020  | 34.0%  | 79.8%  | 10.0%   | 0.4    | 151.4  |
| 2019-2021  | 53.0%  | 79.8%  | 7.0%    | 0.5    | 247.6  |
| 2020-2022  | 64.0%  | 79.8%  | 65.0%   | 0.4    | 328.0  |
| 2021-2023  | 125.0% | 78.9%  | 124.0%  | 0.2    | 522.6  |
| 2022-2024  | 134.0% | 81.2%  | 113.0%  | 0.2    | 692.1  |
| 2023-2025  | 197.0% | 83.5%  | 132.0%  | 0.2    | 960.5  |

*   **CAGR (Compound Annual Growth Rate):** CAGR has been increasing significantly over the periods, indicating strong growth in the stock's value.
*   **MDD (Maximum Drawdown):** The MDD is consistently high, indicating a significant level of potential downside risk during these periods.
*   **Alpha:** The Alpha values are generally positive and increasing, especially in recent years, meaning the stock has outperformed its benchmark.
*   **Beta:** The Beta values are relatively low (close to 0), indicating that the stock has low volatility relative to the market.
*   **Cap(B) (Market Capitalization in Billions):** Market cap has grown substantially, reflecting the company's expanding size and influence.

**2. Recent Stock Price Fluctuations**

*   **Current Close:** 1071.44
*   **Previous Close:** 1056.88
*   **Change:** 1.38%
*   **5-day SMA:** 1057.318
*   **20-day SMA:** 1042.5557
*   **60-day SMA:** 931.1742

**Analysis:**

The stock is trading above its 5-day, 20-day, and 60-day Simple Moving Averages (SMAs), suggesting an upward trend.  The short-term SMAs are closer to the current price than the long-term SMA, indicating that the recent upward momentum is relatively strong.

**3. Indicators Analysis**

*   **Market Risk Indicator (MRI):** 0.7 (Medium Investment Recommended)
*   **RSI:** 55.59 (Neutral, neither overbought nor oversold)
*   **PPO:** -0.2291 (Slightly below zero, indicating slightly bearish momentum but is very close to the signal line.)
*   **Hybrid Signal:** "cash_0%_Buy 100% of cash (1 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00)" - Suggests a strong buy signal based on a composite analysis.
*   **Recent (20 days) relative divergence change:** 5.8 (+) - 단기상승 (Short-term increase)
*   **Expected Return (%):** 49.2% - Indicates a high expected return compared to the S&P 500.

**Analysis:**

The MRI suggests a medium investment recommendation. The RSI is in a neutral zone. The negative PPO value indicates a slightly bearish trend, but it is very close to the signal line and could change quickly. The hybrid signal and expected return suggest a positive outlook for the stock's long-term performance. The recent increase in relative divergence reinforces this positive outlook.

**4. Recent News & Significant Events**

*   **Price Cut of Zepbound:** Eli Lilly slashed the price of Zepbound, leading to a stock drop, but some consider it a buying opportunity.
*   **Shares Sold by Voya Investment Management:** Voya Investment Management sold shares of LLY.
*   **Analyst Target Price Increases:** Analysts are lifting target prices for LLY, citing momentum in the obesity pipeline.
*   **Another Major Win:** Positive news may signal a buying opportunity.
*   **Stock Rose 4% This Week:**  Positive data supports the stock's upward momentum.
*   **Bank of America's Positive Outlook:** BofA believes the market isn't fully pricing in Eli Lilly's potential dominance in weight-loss drugs.

**Analysis:**

The news is mixed. While the Zepbound price cut initially caused a stock drop, analysts seem optimistic about the company's future, particularly regarding its weight-loss drug pipeline. The stock's recent rise and BofA's comments further reinforce this positive sentiment. The sale of shares by Voya should be monitored but may not be a major cause for concern given the overall positive outlook.

**4-2. Analyst Opinions**

*   **Consensus:** Buy
*   **Mean Rating:** 1.70 (~Buy)
*   **Opinions:** 27
*   **Target Price:** $1093.22 (avg) / $1500.00 (high) / $770.00 (low)

**Analysis:**

The analyst consensus is a "Buy" with a mean rating suggesting moderate bullish sentiment. The average target price is slightly above the current price, suggesting potential upside. The high target price indicates significant optimism from some analysts.

**5. Recent Earnings Analysis**

| Date       | EPS  | Revenue   |
|------------|------|-----------|
| 2025-10-30 | 6.22 | 17.60 B$  |
| 2025-08-07 | 6.30 | 15.56 B$  |
| 2025-05-01 | 3.07 | 12.73 B$  |
| 2024-10-30 | 1.08 | 11.44 B$  |
| 2025-10-30 | 1.08 | 11.44 B$  |

**Analysis:**

The table presents the information twice in error. Corrected table:

| Date       | EPS  | Revenue   |
|------------|------|-----------|
| 2025-10-30 | 6.22 | 17.60 B$  |
| 2025-08-07 | 6.30 | 15.56 B$  |
| 2025-05-01 | 3.07 | 12.73 B$  |
| 2024-10-30 | 1.08 | 11.44 B$  |

Earnings per share (EPS) and revenue have shown significant growth in recent quarters. The increase in EPS from $1.08 in 2024-10-30 to $6.22 in 2025-10-30, along with the consistent revenue growth, indicates strong financial performance.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $17.60B   | 82.91%        |
| 2025-06-30   | $15.56B   | 84.27%        |
| 2025-03-31   | $12.73B   | 82.53%        |
| 2024-12-31   | $13.53B   | 82.24%        |
| 2024-09-30   | $11.44B   | 81.02%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE       |
|--------------|-----------|-----------|
| 2025-09-30   | $23.79B   | 23.46%    |
| 2025-06-30   | $18.27B   | 30.98%    |
| 2025-03-31   | $15.76B   | 17.50%    |
| 2024-12-31   | $14.19B   | 31.07%    |
| 2024-09-30   | $14.24B   | 6.81%     |

**Analysis:**

*   **Revenue:** Revenue has been consistently increasing, demonstrating strong sales performance.
*   **Profit Margin:** High and stable profit margins indicate efficient operations and pricing power.
*   **Equity:** Equity has been increasing, demonstrating the company's growing net worth.
*   **ROE (Return on Equity):** The ROE has fluctuated, with significant increases in certain quarters, indicating efficient use of equity to generate profits. The low ROE in 2024-09-30 should be considered in light of overall positive trends.

**7. Comprehensive Analysis**

Eli Lilly and Co. (LLY) presents a compelling investment case based on the analyzed data.

*   **Performance:**  The stock has significantly outperformed the S&P 500, and recent gains suggest continued momentum.
*   **Financials:** Strong revenue growth, high profit margins, and increasing equity demonstrate the company's financial health.
*   **Analysts:**  Analysts are generally bullish, with "Buy" ratings and increasing target prices.
*   **News:**  Positive developments in the weight-loss drug pipeline are a key driver of optimism.  The Zepbound price cut, while causing a temporary dip, could be a strategic move for long-term market dominance.
*   **Indicators:**  While some indicators like the PPO suggest slight bearish momentum, the hybrid signal, MRI and high expected return signal a positive overall investment outlook.
*   **Risk:**  The high MDD values indicate significant potential downside risk, a factor to consider for risk-averse investors.
* **Disclaimer**: The stock information provided here is solely for informational purposes. This is not financial advice. Consult with a financial advisor before making investment decisions.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.